Clinical impact of direct HDLc and LDLc method bias in hypertriglyceridemia. A simulation study of the EAS-EFLM Collaborative Project Group

Atherosclerosis

Volumn 233, Issue 1, 2014, Pages 83-90

  Langlois, Michel R ^a,b,c   Descamps, Olivier S ^d   van der Laarse, Arnoud ^e   Weykamp, Cas ^f   Baum, Hannsjörg ^a,g   Pulkki, Kari ^a,h   von Eckardstein, Arnold ⁱ   De Bacquer, Dirk ^j   Borén, Jan ^k   Wiklund, Olov ^k   Laitinen, Païvi ^a   Oosterhuis, Wytze P ^b   Cobbaert, Christa ^e  

^a European Federation of Clinical Chemistry and Laboratory Medicine (EFLM)   (United Kingdom)

^b WG Guidelines EFLM ^*  (United Kingdom)

^c General Hospital St Jan   (Belgium)

^d Hospital de Jolimont   (Belgium)

^e LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^f Queen Beatrix Hospital   (Netherlands)

^g Regionale Kliniken Holding RKH GmbH   (Germany)

^h UNIVERSITY OF EASTERN FINLAND   (Finland)

ⁱ UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^j GHENT UNIVERSITY   (Belgium)

^k UNIVERSITY OF GOTHENBURG   (Sweden)

more..

Author keywords

HDL cholesterol; Hypertriglyceridemia; LDL cholesterol; Risk classification; SCORE; Treatment goals

Indexed keywords

HDL-CHOLESTEROL; HYPERTRIGLYCERIDEMIA; LDL-CHOLESTEROL; RISK CLASSIFICATION; SCORE; TREATMENT GOALS;

BIAS (EPIDEMIOLOGY); CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DIAGNOSTIC ERRORS; FEMALE; HUMANS; HYPERTRIGLYCERIDEMIA; MALE; REPRODUCIBILITY OF RESULTS; RISK FACTORS;

EID: 84893878053     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2013.12.016     Document Type: Article

References (50)

1. Catapano A.L., Reiner Z., De Backer G., et al. ESC/EAS guidelines for the management of dyslipidaemias. The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis 2011, 217:3-46.
2. Descamps O.S., Cooney M.T., De Backer G., Graham I. Asimple multiplier to calculate the impact of HDL cholesterol on cardiovascular risk estimation using SCORE. Atherosclerosis 2012, 222:564-566.
3. Haase C.L., Tybjærg-Hansen A., Qayyum A.A., Schou J., Nordestgaard B.G., Frikke-Schmidt R. LCAT, HDL cholesterol and ischemic cardiovascular disease: a Mendelian randomization study of HDL cholesterol in 54,500 individuals. JClin Endocrinol Metab 2012, 97:E248-E256.
4. Voight B.F., Peloso G.M., Orho-Melander M., et al. Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet 2012, 380:572-580.
5. Langlois M., Blaton V. Historical milestones in the measurement of HDL cholesterol: impact on clinical and laboratory practice. Clin Chim Acta 2006, 369:168-178.
6. Warnick G.R., Nauck M., Rifai N. Evolution of methods for measurement of HDL-cholesterol: from ultracentrifugation to homogeneous assays. Clin Chem 2001, 47:1579-1596.
7. Nauck M., Warnick G.R., Rifai N. Methods for measurement of LDL-cholesterol: a critical assessment of direct measurement by homogeneous assays versus calculation. Clin Chem 2002, 48:236-254.
8. McNamara J.R., Warnick G.R., Cooper G.R. Abrief history of lipid and lipoprotein measurements and their contribution to clinical chemistry. Clin Chim Acta 2006, 369:158-167.
9. Miller W.G., Myers G.L., Sakurabayashi I., et al. Seven direct methods for measuring HDL and LDL cholesterol compared with ultracentrifugation reference measurement procedures. Clin Chem 2010, 56:977-986.
10. Cobbaert C., Zwang L., Ceriotti F., et al. Reference standardization and triglyceride interference of a new homogeneous HDL-cholesterol assay compared with a former chemical precipitation assay. Clin Chem 1998, 44:779-789.
11. Contois J.H., Warnick G.R., Sniderman A.D. Reliability of low-density lipoprotein cholesterol, non-high density lipoprotein cholesterol, and apolipoprotein B measurement. JClin Lipidol 2011, 5:264-272.
12. Langlois M.R., Delanghe J.R., De Buyzere M., Rietzschel E., De Bacquer D. Unanswered questions in including HDL cholesterol in the cardiovascular risk estimation. Is time still on our side?. Atherosclerosis 2013, 226:296-298.
13. Leiviskä J., Sundvall J., Alfthan G., et al. What have we learnt about high-density lipoprotein cholesterol measurements during 32 years? Experiences in Finland 1980-2012. Clin Chim Acta 2013, 415:118-123.
14. Vesper H.W., Wilson P.W.F., Rifai N. Amessage from the laboratory community to the National Cholesterol Education Program Adult Treatment Panel IV. Clin Chem 2012, 58:523-527.
15. Caudill P., Cooper G.R., Jay Smith S., Myers G.L. Assessment of current National Cholesterol Education Program guidelines for total cholesterol, triglycerides, HDL-cholesterol, and LDL-cholesterol measurements. Clin Chem 1998, 44:1650-1658.
16. Cobbaert C., Weykamp C., Baadenhuijsen H., Kuypers A., Lindemans J., Jansen R. Selection, preparation, and characterization of commutable frozen human serum pools as potential secondary reference materials for lipid and apolipoprotein measurements: study within the framework of the Dutch project "Calibration 2000". Clin Chem 2002, 48:1526-1538.
17. Baadenhuijsen H., Kuypers A., Weykamp C., Cobbaert C., Jansen R. External quality assessment in the Netherlands: time to introduce commutable survey specimens. Lessons from the Dutch "Calibration 2000" project. Clin Chem Lab Med 2005, 43:304-307.
18. Clinical and Laboratory standards Institute (CLSI) Preparation and validation of commutable frozen human serum pools as secondary reference materials for cholesterol measurement procedures; approved guideline 1999, CLSI document C37-A, CLSI, Wayne (PA) USA.
19. Marcovina S.M., Albers J.J., Kennedy H., Mei J.V., Henderson L.O., Hannon W.H. International federation of clinical chemistry standardization project for measurements of apolipoprotein A-I and B. IV comparability of apolipoprotein B values by use of international reference material. Clin Chem 1994, 40:586-592.
20. Friedewald W.T., Levy R.I., Fredrickson D.S. Estimation of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972, 18:499-502.
21. Bachorik P.S., Ross J.W. National Cholesterol Education Program recommendations for measurement of low-density lipoprotein cholesterol: executive summary. Clin Chem 1995, 41:1414-1420. for the NCEP Working Group on Lipoprotein Measurement.
22. Warnick G.R., Wood P.D. National Cholesterol Education Program recommendations for measurement of high-density lipoprotein cholesterol: executive summary. Clin Chem 1995, 41:1427-1433. for the National Cholesterol Education Program Working Group on Lipoprotein Measurement.
23. Warnick G.R., Kimberly M.M., Waymack P.P., Leary E.T., Myers G.L. Standardization of measurements for cholesterol, triglycerides, and major lipoproteins. Lab Med 2008, 39:481-490.
24. Kimberly M., Leary E.T., Cole T.G., Waymack P.P. Selection, validation, standardization, and performance of a designated comparison method for HDL-cholesterol for use in the cholesterol reference method laboratory network. Clin Chem 1999, 45:1803-1812. for the Cholesterol Reference Method Laboratory Network.
25. Miller W.G., Waymack P.P., Anderson F.P., Ethridge S.F., Jayne E.C. Performance of four homogeneous direct methods for LDL-cholesterol. Clin Chem 2002, 489-498.
26. Miida T., Nishimura K., Okamura T., et al. Amulticenter study on the precision and accuracy of homogeneous assays for LDL-cholesterol: comparison with a beta-quantification method using fresh serum obtained from non-diseased and diseased subjects. Atherosclerosis 2012, 225:208-215.
27. Esteban-Salán M., Guimón-Bardesi A., de la Viuda-Unzueta J.M., Azcarate-Ania M.N., Pascual-Usandizaga P., Amoroto-Del-Rio E. Analytical and clinical evaluation of two homogeneous assays for LDL-cholesterol in hyperlipidemic patients. Clin Chem 2000, 46:1121-1131.
28. Mora S., Rifai N., Buring J.E., Ridker P.M. Comparison of LDL cholesterol concentrations by Friedewald calculation and direct measurement in relation to cardiovascular events in 27,331 women. Clin Chem 2009, 55:888-894.
29. van Deventer H.E., Miller W.G., Myers G.L., et al. Non-HDL-cholesterol shows improved accuracy for cardiovascular risk score classification compared to direct or calculated LDL cholesterol in a dyslipidemic population. Clin Chem 2011, 57:490-501.
30. Langlois M.R. Laboratory approaches for predicting and managing the risk of cardiovascular disease: postanalytical opportunities of lipid and lipoprotein testing. Clin Chem Lab Med 2012, 50:1169-1181.
31. Rosenson R.S., Brewer H.B., Chapman M.J., et al. HDL measures, particle heterogeneity, proposed nomenclature, and relation to atherosclerotic cardiovascular events. Clin Chem 2011, 57:392-410.
32. Rye K.A., Barter P.J. Predictive value of different HDL particles for the protection against or risk of coronary heart disease. Biochim Biophys Acta 2012, 1821:473-480.
33. Bookstein L., Gidding S.S., Donovan M., Smith G.A. Impact of day-to-day variability of serum cholesterol, triglycerides, and HDL cholesterol on the assessment of risks according to the National Cholesterol Education Program guidelines. Arch Intern Med 1990, 150:1653-1657.
34. Varbo A., Benn M., Tybjærg-Hansen A., Jørgensen A.B., Frikke-Schmidt R., Nordestgaard B.G. Remnant cholesterol as a causal risk factor for ischemic heart disease. JAm Coll Cardiol 2013, 61:427-436.
35. Stein E.A., Myers G.L. National Cholesterol Education Program recommendations for triglyceride measurement: executive summary. Clin Chem 1995, 41:1421-1426.
36. Walldius G., Jungner I. Apolipoprotein B and apolipoprotein A-I: risk indicators of coronary heart disease and targets for lipid-modifying therapy-a review of the evidence. JIntern Med 2004, 255:188-205.
37. Sniderman A.D., Williams K., Contois J.H., et al. Ameta-analysis of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular risk. Circ Cardiovasc Qual Outcomes 2011, 4:337-345.
38. Cole T.G., Contois J.H., Csako C., et al. Association of apolipoprotein B and nuclear magnetic resonance spectroscopy-derived LDL particle number with outcomes in 25 clinical studies: assessment by the AACC Lipoprotein and Vascular Diseases Division Working Group on Best Practices. Clin Chem 2013, 59:752-770.
39. Lipid-related markers and cardiovascular disease prediction. JAm Med Assoc 2012, 307:2499-2506. Emerging Risk Factors Collaboration.
40. Sniderman A.D., Islam S., Yusuf S., McQueen M.J. Discordance analysis of apolipoprotein B and non-high density lipoprotein cholesterol as markers of cardiovascular risk in the INTERHEART study. Atherosclerosis 2012, 225:444-449.
41. Masana L., Ibarretxe D., Heras M., et al. Substituting non-HDL cholesterol with LDL as a guide for lipid-lowering therapy increases the number of patients with indication for therapy. Atherosclerosis 2013, 226:471-475.
42. Boekholdt S.M., Arsenault B.J., Mora S., et al. Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis. JAm Med Assoc 2012, 307:1302-1309.
43. Robinson J.G., Wang S., Jacobson T.A. Meta-analysis of comparison of effectiveness of lowering apolipoprotein B versus low-density lipoprotein cholesterol and non high-density lipoprotein cholesterol for cardiovascular risk reduction in randomized trials. Am J Cardiol 2012, 110:1468-1476.
44. Mora S., Glynn R.J., Boekholdt S.M., Nordestgaard B.G., Kastelein J.J., Ridker P.M. On-treatment non-high-density lipoprotein cholesterol, apolipoprotein B, triglycerides, and lipid ratios in relation to residual vascular risk after treatment with potent statin therapy: JUPITER (justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin). JAm Coll Cardiol 2012, 59:1521-1528.
45. Davidson M.H., Ballantyne C.M., Jacobson T.A., et al. Clinical utility of inflammatory markers and advanced lipoprotein testing: advice from an expert panel of lipid specialists. JClin Lipidol 2011, 5:338-367.
46. De Bacquer D., De Backer G. Predictive ability of the SCORE Belgium risk chart for cardiovascular mortality. Int J Cardiol 2010, 385-390.
47. Mikhailidis D.P., Elisaf M., Rizzo M., et al. European Panel on low density lipoprotein (LDL) subclasses: a statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses. Curr Vasc Pharmacol 2011, 9:533-571.
48. Davidson M.H., Corson M.A., Alberts M.J., et al. Consensus panel recommendation for incorporating lipoprotein-associated phospholipase A2 testing into cardiovascular disease risk assessment guidelines. Am J Cardiol 2008, 101(Suppl.):51F-57F.
49. Thompson A., Gao P., Orfei L., et al. Lipoprotein-associated phospholipase A2 and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies. Lancet 2010, 375:1536-1544. The Lp-PLA2 Studies Collaboration.
50. Hirayama S., Miida T. Small dense LDL: an emerging risk factor for cardiovascular disease. Clin Chim Acta 2012, 414:215-224.